CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer.

At CG Oncology, we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

Our lead candidate, cretostimogene grenadenorepvec (CG0070), is a targeted oncolytic intravesically-delivered immunotherapy. In BCG unresponsive non-muscle invasive bladder cancer (NMIBC) and other cancer types, the agent has shown promise in potentially delivering a safe and effective therapy alone as well as in combination with other therapies.

Click here to view our Executive Leadership.

Click here to view our Board of Directors.

Unmet Need in Bladder Cancer

people will be diagnosed with Bladder Cancer this year1

Most Common Type of Cancer in men in the US1

Non-muscle invasive bladder
cancer (NMIBC) represents

%

of new bladder cancer cases2

Only

%

of High-Grade patients with T1 disease, where cystectomy is guideline recommended after BCG fails, will undergo a cystectomy3-6

%

will progress to muscle invasive or metastatic bladder cancer within 5 years7

Up to

%

of high-risk patients will
recur within 1 year8

REFERENCES:

1. Cancer of the Urinary Bladder – Cancer Stat Facts. SEER. https://seer.cancer.gov/statfacts/html/urinb.html. Accessed January, 2023.

2. Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM (2016). Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 196:1021-1029.

3. Berger I, Xia L, Wirtalla C, Dowzicky P, Guzzo TJ, Kelz RR. 30-day readmission after radical cystectomy: Identifying targets for improvement using the phases of surgical care. Can Urol Assoc J. 2018;13(7):E190-e201.

4. Sadowski DJ, Warner H, Scaife S, McVary KT, Alanee SR. 30-day all-cause hospital readmission after cystectomy: No worse for rural Medicare residents. Urol Oncol. 2018;36(3):89.e87-89.e11.

5. Pak JS, Lee JJ, Bilal K, Finkelstein M, Palese MA. Utilization trends and short-term outcomes of robotic versus open radical cystectomy for bladder cancer. Urology. 2017;103:117-123.

6. Maiboma SL, Poulsena AM, Thind PO, Sallinga ML, Sallinga LN, Kehletb H, Brassoa K, Joensena UN, (2021). Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer. European Journal of Urology 28(28) 1-8.www.sciencedirect.com

7. Hussain MH, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol. 2009;27(34): 5680-5684.

8.  Richard J Sylvester 1, Adrian P M van der Meijden, Willem Oosterlinck, J Alfred Witjes, Christian Bouffioux, Louis Denis, Donald W W Newling, Karlheinz Kurth. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Uro.  2006 Mar;49(3):466-5; discussion 475-7.  doi: 10.1016/j.eururo.2005.12.031. Epub 2006 Jan 17.